Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news

For patients presenting with limited metastatic disease burden, known as the oligometastatic state of disease, a more aggressive treatment approach targeting the new or progressive metastatic lesions might improve patient outcome, with no or only limited toxicity to be expected from the treatment. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Berghen, Charlien, Joniau, Steven, Vulsteke, Christof, Albersen, Maarten, Devos, Gaëtan, Rans, Kato, Haustermans, Karin, De Meerleer, Gert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289610/
https://www.ncbi.nlm.nih.gov/pubmed/32565889
http://dx.doi.org/10.3332/ecancer.2020.1036
_version_ 1783545497377570816
author Berghen, Charlien
Joniau, Steven
Vulsteke, Christof
Albersen, Maarten
Devos, Gaëtan
Rans, Kato
Haustermans, Karin
De Meerleer, Gert
author_facet Berghen, Charlien
Joniau, Steven
Vulsteke, Christof
Albersen, Maarten
Devos, Gaëtan
Rans, Kato
Haustermans, Karin
De Meerleer, Gert
author_sort Berghen, Charlien
collection PubMed
description For patients presenting with limited metastatic disease burden, known as the oligometastatic state of disease, a more aggressive treatment approach targeting the new or progressive metastatic lesions might improve patient outcome, with no or only limited toxicity to be expected from the treatment. This review provides an overview of the existing evidence and on-going trials on oligometastatic disease and metastasis-directed therapy in the field of renal, bladder and prostate cancer.
format Online
Article
Text
id pubmed-7289610
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-72896102020-06-19 Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news Berghen, Charlien Joniau, Steven Vulsteke, Christof Albersen, Maarten Devos, Gaëtan Rans, Kato Haustermans, Karin De Meerleer, Gert Ecancermedicalscience Review For patients presenting with limited metastatic disease burden, known as the oligometastatic state of disease, a more aggressive treatment approach targeting the new or progressive metastatic lesions might improve patient outcome, with no or only limited toxicity to be expected from the treatment. This review provides an overview of the existing evidence and on-going trials on oligometastatic disease and metastasis-directed therapy in the field of renal, bladder and prostate cancer. Cancer Intelligence 2020-05-07 /pmc/articles/PMC7289610/ /pubmed/32565889 http://dx.doi.org/10.3332/ecancer.2020.1036 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Berghen, Charlien
Joniau, Steven
Vulsteke, Christof
Albersen, Maarten
Devos, Gaëtan
Rans, Kato
Haustermans, Karin
De Meerleer, Gert
Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news
title Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news
title_full Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news
title_fullStr Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news
title_full_unstemmed Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news
title_short Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news
title_sort metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289610/
https://www.ncbi.nlm.nih.gov/pubmed/32565889
http://dx.doi.org/10.3332/ecancer.2020.1036
work_keys_str_mv AT berghencharlien metastasisdirectedtherapyforoligometastaticurologicaltumoursstillnosecondhandnews
AT joniausteven metastasisdirectedtherapyforoligometastaticurologicaltumoursstillnosecondhandnews
AT vulstekechristof metastasisdirectedtherapyforoligometastaticurologicaltumoursstillnosecondhandnews
AT albersenmaarten metastasisdirectedtherapyforoligometastaticurologicaltumoursstillnosecondhandnews
AT devosgaetan metastasisdirectedtherapyforoligometastaticurologicaltumoursstillnosecondhandnews
AT ranskato metastasisdirectedtherapyforoligometastaticurologicaltumoursstillnosecondhandnews
AT haustermanskarin metastasisdirectedtherapyforoligometastaticurologicaltumoursstillnosecondhandnews
AT demeerleergert metastasisdirectedtherapyforoligometastaticurologicaltumoursstillnosecondhandnews

Ejemplares similares